LENZ Therapeutics, Inc. (LENZ)
3.20
-0.30
(-8.57%)
USD |
NASDAQ |
Nov 18, 16:00
3.21
+0.01
(+0.31%)
After-Hours: 20:00
LENZ Therapeutics Max Drawdown (5Y) : 97.31% for Oct. 31, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| October 31, 2026 | 97.31% |
| September 30, 2026 | 97.31% |
| August 31, 2026 | 97.31% |
| July 31, 2026 | 97.31% |
| June 30, 2026 | 97.28% |
| May 31, 2026 | 96.71% |
| April 30, 2026 | 95.90% |
| March 31, 2026 | 95.90% |
| Date | Value |
|---|---|
| February 28, 2026 | 94.27% |
| January 31, 2026 | 93.98% |
| December 31, 2025 | 93.98% |
| November 30, 2025 | 93.98% |
| October 31, 2025 | 93.98% |
| September 30, 2025 | 93.98% |
| August 31, 2025 | 93.98% |
| July 31, 2025 | 93.98% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| EyePoint, Inc. | 98.83% |
| Ligand Pharmaceuticals, Inc. | 72.85% |
| Bristol Myers Squibb Co. | 47.67% |
| Context Therapeutics, Inc. | 97.36% |
| Neumora Therapeutics, Inc. | -- |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -58.76 |
| Beta (5Y) | 0.7855 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 67.93% |
| Historical Sharpe Ratio (5Y) | -0.77 |
| Historical Sortino (5Y) | -1.166 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 38.93% |